[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"xieqing\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":5},"100634261",false,"NCT07537387","A Study on the Pursuit of Sustained Clearance of HBsAg in Chronic Hepatitis B(CHB) Patients With Previous Interferon Treatment Using Pegylated Interferon Alpha","A Prospective, Non-Randomized, Multicenter Study of Peginterferon Alfa for Pursuing Sustained Hepatitis B Surface Antigen(HBsAg) Clearance in Interferon-Pretreated Patients With Chronic Hepatitis B","Inclusion Criteria:\n\n* • Voluntary participation and ability to understand and provide written informed consent.\n\n  * Age 18-65 years (inclusive), either gender.\n  * Documented HBsAg positivity for at least 6 months, or other evidence confirming chronic hepatitis B (CHB).\n  * Prior interferon therapy before enrollment (treatment discontinuation ≥ 3 months), with HBsAg level at the end of prior treatment reduced by ≥ 50% from baseline.\n  * HBsAg ≤ 500 IU\u002FmL at screening, and HBsAg rebound at screening not exceeding 50% of the baseline HBsAg level during the first-round interferon therapy.\n  * Negative pregnancy test within 24 hours prior to the first dose (for women of childbearing potential); all subjects (male and female) must use effective contraceptive measures during the study.\n\nExclusion Criteria:\n\n* • Pregnant or lactating women, or subjects with a pregnancy plan during the study period.\n\n  * Subjects with neuropsychiatric disorders, in particular a history of depression, anxiety, mania, schizophrenia, or a family history of psychiatric disorders (especially a history of depression or depressive tendency).\n  * Concurrent active infection with hepatitis A, hepatitis C, hepatitis E and\u002For HIV, or chronic liver disease due to other causes (e.g., alcoholic hepatitis, drug-induced liver injury, autoimmune liver disease, etc.).\n  * Evidence of acute severe liver damage: e.g., ALT \\> 10 × ULN, or marked ALT elevation accompanied by significant hyperbilirubinemia.\n  * Evidence of decompensated liver disease: e.g., ascites, esophagogastric variceal bleeding, sepsis, hepatic encephalopathy, hepatorenal syndrome, etc.; or prior evidence of decompensated cirrhosis.\n  * Evidence of hepatocellular carcinoma (HCC), or AFP \\> 1 × ULN.\n  * Renal diseases: acute or chronic nephritis, renal insufficiency, nephrotic syndrome, etc.; or serum creatinine \\> 1 × ULN at screening.\n  * Neutrophil count \\\u003C 1.5 × 10⁹\u002FL, platelet count \\\u003C 90 × 10⁹\u002FL, or serum phosphorus \\\u003C 0.8 mmol\u002FL during the screening period.\n  * Autoimmune diseases (e.g., psoriasis, systemic lupus erythematosus, etc.), endocrine disorders (e.g., thyroid diseases, diabetes, etc.), hypertension poorly controlled by prescription medications (blood pressure ≥ 140\u002F90 mmHg), a history of severe heart disease (especially poorly controlled within 6 months), severe retinopathy or other serious ophthalmologic diseases, or other organic lesions or dysfunction of vital organs.\n  * Subjects planning to undergo or having previously undergone organ transplantation.\n  * Subjects with hypersensitivity to the investigational product or its excipients, or meeting any contraindication listed in the prescribing information of the investigational product.\n  * Other conditions deemed inappropriate for enrollment by the investigator","ALL","18 Years","65 Years",{"count":19,"type":20},10000,"ESTIMATED","OBSERVATIONAL","This is a real-world, prospective, multicenter, non-randomized, controlled study. It aims to investigate the efficacy and safety of pegylated interferon α-2b (PEG IFN α-2b) monotherapy versus its combination with nucleos(t)ide analogs (NAs) regarding hepatitis B surface antigen (HBsAg) clearance in interferon-experienced patients with chronic hepatitis B (CHB). Subjects will receive either interferon-based therapy or NAs monotherapy based on their personal willingness and physicians' professional recommendations, with a uniform 48-week treatment course for all enrolled patients.",[24],"Chronic Hepatitis b",[26,27,28],"CHB","Peginterferon","retreatment","NOT_YET_RECRUITING","2026-04-15",{"date":32,"type":33},"2026-04-17","ACTUAL",{"date":35,"type":20},"2026-04-30",{"date":37,"type":20},"2030-12-31",{"name":39,"class":40},"xieqing","OTHER",""]